Johnson & Johnson Submits FDA Supplemental Biologics License Application And New Drug Application For Rybrevant Plus Lazertinib For First-line Treatment Of EGFR-Mutated Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson has submitted applications to the FDA for Rybrevant and Lazertinib as a combined first-line treatment for EGFR-mutated non-small cell lung cancer. The submission includes a Supplemental Biologics License Application (sBLA) and a New Drug Application (NDA), indicating progress in expanding treatment options for this type of cancer.
December 21, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's submission of sBLA and NDA for Rybrevant and Lazertinib could expand its oncology portfolio and potentially increase revenue if approved by the FDA.
The submission of these applications to the FDA is a positive step for Johnson & Johnson, indicating potential growth in its oncology segment. If approved, the treatment could become a significant revenue driver, especially considering the high prevalence of non-small cell lung cancer. The news is likely to be viewed positively by investors, as it demonstrates progress in the company's product pipeline.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80